A second Phase II trial of Xanamem in the treatment of Diabetes Cognitive Impairment

Trial Profile

A second Phase II trial of Xanamem in the treatment of Diabetes Cognitive Impairment

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs UE 2343 (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2017 New trial record
    • 26 Apr 2017 According to an Actinogen Medical media release, this trial has been proposed by the University of Edinburgh and is expected to begin in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top